Genzyme Optimistic About Renagel’s Future Despite Fresenius’ Deal For PhosLo
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme CEO does not think Fresenius will inappropriately push physicians to prescribe PhosLo.
You may also be interested in...
Clinical Researcher Debarments Proceeding Slowly, Despite FDA Promises Of Reform
It still takes years to debar a physician convicted of a crime from conducting clinical research.
Clinical Researcher Debarments Proceeding Slowly, Despite FDA Promises Of Reform
It still takes years to debar a physician convicted of a crime from conducting clinical research.
Genzyme Gets Mixed Results On Renvela Powder Formulation
An NDA for the tablet form of the follow-on chronic kidney disease therapy is pending at FDA.